Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab plus standard therapy versus standard therapy in advanced HER2-positive biliary tract cancer
CTR20251721Phase 3Active
- Sponsor
- BeiGene
- Start
- Oct 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of zanidatamab in biliary cancer, sponsored by BeiGene. Started Oct 2025; status: active.
02
Drugs
zanidatamab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20251721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251721.